Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer said that 17 European countries have agreed to extend its Celebrex drug labeling to include symptomatic relief in the treatment of ankylosing spondylitis, a form of arthritis that affects the spine.
Subscribe to our email newsletter
Pfizer added that once each country updates its labeling, Celebrex will be the first oral selective COX-2 inhibitor available in Europe to treat this form of arthritis. Pfizer said that ankylosing spondylitis affects up to 0.9% of Europeans.
Rory O’Connor, vice president, medical and regulatory affairs, Europe, said: “Celebrex now offers an effective and well-tolerated treatment, adding to physician and patient choice in managing this devastating disease.”